What Kite and Novartis developed are known as autologous gene therapies. What Allogene is pursuing is an allogeneic therapy.
The new Right to Try legislation comes as a culmination of a movement that has resulted in similar laws in 40 states. However, the new law has drawn fire from a variety of healthcare stakeholders who worry about the consequences of bypassing current FDA protocols — potential harm to patients and increased liability
The Department of Health and Human Services (HHS) published a Proposed Rule on May 7th asking for a one-year delay for implementing the January 2017 final rule under the 304B Drug Pricing Program. The delay has been granted
Pharmacy benefits managers (PBMs), private firms that contract with health insurers to process and administer claims, are an integral part of the current pharmaceutical administration process. However, some of the current practices of PBMs have drawn significant criticism.
While opinions about the American healthcare system can vary widely, one thing that most experts agree on is that it is becoming increasingly more complex.